NSCLC still has a poor prognosis and immunotherapy (IMT) has become part of the treatment for patients without driver alterations (epidermal growth factor receptor, EGFR, or anaplastic lymphoma kinase, ALK). This evidence concerns the gene ALK and non-small cell lung carcinoma.